Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
A trio of aging-focused biotechs and research firms formed a joint venture to develop small molecules for a novel target hoping to extend life spans.
Profusa raised more than $45 million in a series C round for its tissue-integrated biosensors.
FundamentalVR launched a virtual surgery platform that uses physical feedback to create a tactile, flight simulator-like experience for surgeons.
Medtronic’s new patient engagement program aims to use game-design elements to encourage diabetes patients to better track their blood glucose levels.
GN Hearing unveiled the first in a new category of its ReSound LiNX 3D line of hearing aids, which it dubs as “premium-plus,” at a higher price point.
The FDA approved the first in a new class of hormonal contraceptives: a reusable, flexible ring that can be used for an entire year.
Adherium launched its digital inhaler add-on in the U.S., following a recent 510(k) clearance allowing it to sell the devices directly to consumers.
Former Fierce 15 winner MaxQ plans to go public with $8 million IPO, as it awaits FDA approval of its AI tech for analyzing CT scans for brain bleeds.
Senseonics’ long-term CGM is now available in clinics across the U.S. and has secured its first commercial payer.
Akili brought its series C total up to $68 million while it awaits an FDA decision on its prescription video game for pediatric ADHD.